Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.35 |
| ▸ | PEPD | P12955 | 1/20 | 0.54 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3413778 | 1.00 | PEPD (0.54) | PEPDGABRR1MEN1KMT2ABLM | |
| Hydrochloric Acid SCHEMBL22090369 | 1.00 | PEPD (0.54) | PEPDGABRR1MEN1KMT2ABLM | |
| Hydrochloric Acid SCHEMBL28039954 | 1.00 | PEPD (0.54) | PEPDGABRR1MEN1KMT2ABLM | |
| Hydrochloric Acid SCHEMBL999765 | 1.00 | PEPD (0.54) | PEPDGABRR1MEN1KMT2ABLM | |
| Hydrochloric Acid SCHEMBL15268600 | 0.98 | PEPD (0.52) | PEPDGABRR1MEN1KMT2ABLM | |
| Hydrochloric Acid SCHEMBL15268598 | 0.98 | PEPD (0.52) | PEPDGABRR1MEN1KMT2ABLM | |
| Hydrochloric Acid SCHEMBL15268597 | 0.98 | PEPD (0.52) | PEPDGABRR1MEN1KMT2ABLM | |
| SCHEMBL5346790 | 0.97 | — | — | |
| SCHEMBL2562267 | 0.97 | — | — | |
| SCHEMBL56195 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112566632-A | Bioreactive compositions and methods of use thereof | 加利福尼亚大学董事会 | 2021-03-26 | — | — | CN | disclosed |
| CN-112105350-A | Inhibitors of integrin alpha 2 beta 1 and methods of use | 加利福尼亚大学董事会 | 2020-12-18 | — | — | CN | disclosed |
| EP-3110802-B1 | ETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-10-10 | — | — | EP | disclosed |
| CN-108137477-A | Therapeutic compounds and its application method | 基因泰克公司 | 2018-06-08 | — | — | CN | disclosed |
| US-9725416-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160362383-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9487554-B2 | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-11-08 | — | — | US | disclosed |
| CN-103827133-B | Estra-1, 3,5(10), 16-tetraene-3-carboxamide derivatives, method for the production thereof, pharmaceutical preparations containing the same, and use thereof for producing medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| US-20140249119-A1 | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | US | disclosed |
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2006107948-A9 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | ACADIA PHARM INC (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060252744-A1 | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents | ACADIA PHARMACEUTICALS INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006107948-A2 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060199798-A1 | Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | EK FREDRIK | 2006-09-07 | — | — | US | disclosed |
| EP-1696931-A2 | AMINO SUBSTITUTED DIARYL [A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Acadia Pharmaceuticals Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060194784-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | EK FREDRIK | 2006-08-31 | — | — | US | disclosed |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005063254-A2 | AMINO SUBSTITUTED DIARYL[A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-5021439-A | Senile dementia and memory dysfunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-04 | — | — | US | disclosed |
| EP-0367393-A2 | New heterocyclic compounds, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRM1 | ACE 704/4885PEPD 678/4885GABRR1 385/4885 |
| US-20060252744-A1 | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents | DRD3, DRD2, PNMT | ACE 3783/4885PEPD 2973/4885GABRR1 621/4885 |
| US-20060194784-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | CHRM4, CHRM5, CHRNA10 | ACE 605/4885PEPD 479/4885GABRR1 448/4885 |
| US-20160362383-A1 | ETHYNYL DERIVATIVES | GRIA4, GRM4, GRM2 | ACE 2723/4885PEPD 2472/4885GABRR1 488/4885 |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | CHRM4, CHRM5, CHRNA10 | ACE 605/4885PEPD 479/4885GABRR1 448/4885 |
| US-20140249119-A1 | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments | AKR1A1, AKR1C3, AKR1C1 | ACE 253/4885PEPD 609/4885GABRR1 1650/4885 |
| US-20060199798-A1 | Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | OPRL1, CHRM4, CNR1 | ACE 890/4885PEPD 688/4885GABRR1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.